戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 aricella (chickenpox) and herpes zoster (HZ, shingles).
2 of varicella (chickenpox) and herpes zoster (shingles).
3 ricella (chickenpox) and herpes zoster (HZ) (shingles).
4 ative agent of chickenpox and herpes zoster (shingles).
5 th varicella (chickenpox) and herpes zoster (shingles).
6 40 years, it can give rise to herpes zoster (shingles).
7 ganglia, reactivates to cause herpes zoster (shingles).
8  is a herpesvirus that causes chickenpox and shingles.
9 lla-zoster virus (VZV) causes chickenpox and shingles.
10 lla-Zoster virus (VZV) causes chickenpox and shingles.
11 fic immunity to reinforce protection against shingles.
12 iquitous pathogen that causes chickenpox and shingles.
13  common pathogen that causes chicken pox and shingles.
14 ZV) is the causative agent of chickenpox and shingles.
15 tency in ganglia, and reactivates to produce shingles.
16 la-zoster virus (VZV) causes chicken pox and shingles.
17 ate, diesel fuel, used motor oil and roofing shingles.
18 n of VZV causes herpes zoster, also known as shingles.
19 utaneous and genital herpes, chickenpox, and shingles.
20 lla-zoster virus (VZV) causes chickenpox and shingles.
21 hout postherpetic neuralgia after unilateral shingles.
22  443) about their histories of chickenpox or shingles.
23 lla-zoster virus (VZV) causes chickenpox and shingles.
24 reactivates as herpes zoster, referred to as shingles.
25 ularly from synthetic materials like asphalt shingles.
26 aricella (chickenpox) and herpes zoster (HZ [shingles]).
27  cerebrovascular events, 205 (CI: 183, 230); shingles, 140 (CI: 104, 184); diabetic polyneuropathy, 5
28 the present vaccine can reactivate and cause shingles, a VZV vaccine based on the ORF63 mutant virus
29 sinusitis/otitis media, frequent episodes of shingles, a widespread fungal nail infection, fungal der
30 a mean density of 339 +/- 97 neurites/mm2 in shingles-affected epidermis compared with a density of 1
31                         The reported risk of shingles after the first dose of Moderna vaccine was hig
32  to persistent symptoms and diseases such as shingles after varicella zoster or rheumatic fever after
33 ree of the most important diseases of aging: shingles, Alzheimer's disease and atherosclerotic cardio
34 onset glioma and histories of chickenpox and shingles among 462 cases and 443 controls in the San Fra
35 ) infects most humans and causes chickenpox, shingles and central nervous system pathologies.
36 that vaccination can reduce the incidence of shingles and might prove effective in patients with Alzh
37              Reactivation is associated with shingles and postherpetic neuralgia, as well as with sev
38             Ms A is a 70-year-old woman with shingles and Ramsay-Hunt syndrome who presented to the e
39 as an antimicrobial agent in algae resistant shingles and treated wood is not expected to pose signif
40 ng materials such as algae-resistant roofing shingles and treated wood products for decks, fences, an
41           Release rates from algae-resistant shingles and treated wood were defined based on surface
42 the most hazardous fuel, followed by asphalt shingles and vinyl plank flooring under smoldering condi
43 irst discovered in a woman with disseminated shingles and were described by Ion Gresser from 1981 to
44 , including herpes zoster (HZ; also known as shingles), and has been implicated in the development of
45 virus, is the causative agent of chickenpox, shingles, and postherpetic neuralgia.
46                       Because chickenpox and shingles are endemic worldwide, understanding the relati
47 activation to recombinant zoster vaccine for shingles at cellular and transcriptional levels.
48 ated for VZV-seropositive persons to prevent shingles but could potentially also protect VZV-seronega
49 human herpesvirus that causes chickenpox and shingles, but its cell-associated nature has hindered st
50                                              Shingles can cause chronic neuropathic pain (postherpeti
51                           Herpes zoster (HZ; shingles) caused by varicella zoster virus reactivation
52                               Herpes zoster (shingles) causes significant morbidity in immune comprom
53 associated procedures, including chickenpox, shingles, cold sores, mononucleosis, mumps, hepatitis B,
54 ss of vaccinations to prevent chickenpox and shingles, combined with the extremely low incidence of a
55 e occurred despite the lack of contralateral shingles eruptions or pain, correlated with the presence
56                          For algae-resistant shingles, exposures did not exceed benchmarks in any med
57    Vaccine recipients had a 73% reduction in shingles following 2 doses.
58 nating immunocompetent patients who have had shingles has not been examined.
59 d that the seasonal cycles of chickenpox and shingles have different underlying mechanisms, with ambi
60         To date, population-level studies of shingles have had to rely on small-scale hospital or com
61 a preclinical candidate to treat chickenpox, shingles (herpes zoster), and herpes simplex virus 1 (HS
62    RZV is a new option for the prevention of shingles in this population.
63           We calculated the rate of incident shingles in time periods relative to vaccination, along
64         They also seem to be associated with shingles in various settings.
65 ic sensory neurons to produce herpes zoster (shingles) in a unilateral dermatomal distribution, typic
66 of varicella (chickenpox) and herpes zoster (shingles) infections commonly involving skin, mucous mem
67 e evaluated from the site of maximum pain or shingles involvement, the homologous contralateral locat
68 cation, and a site on the back, distant from shingles involvement.
69 hood disease with a rich legacy of research, shingles is not a notifiable disease in most countries.
70 eas a vaccine is available for prevention of shingles, its efficacy declines with age.
71 f association with viral diseases, including shingles, led to wide acceptance of the conclusion that
72  It is a key component of human vaccines for shingles, malaria, coronavirus disease 2019 and others u
73             Here, we examined chickenpox and shingles notifications from Thailand and found strong se
74 npox (odds ratio = 0.4, 95% CI 0.3-0.6), and shingles (odds ratio = 0.5, 95% CI 0.3-0.8).
75 .4, 95% confidence interval (CI) 0.3-0.6) or shingles (odds ratio = 0.5, 95% CI 0.3-0.8).
76  a neuroattenuated vaccine candidate against shingles or a vector for delivery of other antigens.
77 and may reactivate later in life, leading to shingles or inflammatory diseases of the nervous system
78 l arteries after either reactivation of VZV (shingles) or primary infection (chickenpox).
79 ing the biological drivers of chickenpox and shingles over an 8-year period to estimate rates of VZV
80             There is a transient increase in shingles presentations shortly after dose 1 of RZV vacci
81 =65 years in Australia, clinician reports of shingles presentations shortly after vaccination emerged
82                Following dose 2, the risk of shingles presentations was reduced in all age groups.
83 e, 10.96; 95% CI, 10.34-11.62; P < .0001) in shingles presentations within 21 days post-dose 1 of RZV
84                                          The Shingles Prevention Study (SPS) demonstrated zoster vacc
85               The Depression Substudy of the Shingles Prevention Study (SPS) was designed to evaluate
86                      After completion of the Shingles Prevention Study (SPS; Department of Veterans A
87                                          The Shingles Prevention Study (SPS; Department of Veterans A
88                                          The Shingles Prevention Study demonstrated that HZ vaccine s
89                                          The Shingles Prevention Study showed that a varicella-zoster
90  Using specimens from the placebo arm of the Shingles Prevention Study, we investigated whether perso
91 tivation causes herpes zoster (HZ), known as shingles, primarily affecting the elderly and individual
92 peak chickenpox transmission season and peak shingles reactivation.
93  ultraviolet radiation being correlated with shingles reactivation.
94                   Individuals afflicted with shingles risk developing the painful condition of posthe
95 nvestigated whether there was an increase in shingles risk immediately post-RZV vaccination in southe
96 presence and severity of ongoing pain at the shingles site, and did not extend to the distant site.
97  neuralgia (PHN) is a common complication of shingles that manifests as prolonged excruciating pain,
98 le neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patien
99 f VZV reactivation are observed in the skin (shingles), the number and functional capacity of cutaneo
100 us and the causative agent of chickenpox and shingles, the latter being particularly associated with
101 kenpox) during primary infection and zoster (shingles) upon reactivation.
102                   To report the frequency of shingles vaccination and HZ reactivation following shing
103 es vaccination and HZ reactivation following shingles vaccination in this population.
104                                              Shingles vaccination rates were low in this study popula
105 f eligible populations, 5333 (1.5%) received shingles vaccination; 43 patients developed reactivation
106 ing the introduction of a funded recombinant shingles vaccine (RZV; Shingrix, GlaxoSmithKline) vaccin
107 lt SOT patients with no history of varicella/shingles vaccine or disease were given 2 doses of RZV va
108                      Whether the recombinant shingles vaccine protects against dementia remains unkno
109                              The recombinant shingles vaccine was also associated with lower risks of
110 er adults immunized with the live attenuated shingles vaccine Zostavax.
111 ded by a doctor among those who received the shingles vaccine, 98.0% (95% CI: 95%-100%), was signific
112 ssible additional benefit of the recombinant shingles vaccine.
113 erging evidence that the live herpes zoster (shingles) vaccine might protect against dementia.
114 oronavirus, respiratory syncytial virus, and shingles vaccines-among adults.
115 g varicella (chicken pox) and herpes zoster (shingles), we generated a full-length infectious bacteri
116 s varicella (chicken pox) and herpes zoster (shingles), while HCMV causes serious disease in immunoco
117 glia, and reactivates decades later to cause shingles (zoster) and other neurologic complications.
118 irus that causes chicken pox (varicella) and shingles (zoster).
119  entire neuraxis, and reactivates to produce shingles (zoster).
120 glia, and reactivates decades later to cause shingles (zoster).

 
Page Top